Navigation Links
Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone

Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion)... -- TCT 2010, WASHINGTON, September 24, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Personnel Announcements, Trade Show News, Clinical Trials & Medical Discoveries Click to view news release full screen  

Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone


TCT 2010, WASHINGTON, September 24, 2010 /PRNewswire/ -- InspireMD announced today the launch of a multinational randomized controlled trial designed to demonstrate MGuard Coronary Stent's superiority over standard care for STEMI (heart attack) patients.

The MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial will enroll 406 patients in a 2-arm, parallel design, with a primary endpoint of complete ST segment resolution post procedure. Clinical follow-up will continue for 1 year and other important secondary endpoints will be measured. Dr. Gregg Stone, Director of Cardiovascular Research and Education from the Columbia University in New-York, who will serve as a study chairman, said "Too often primary PCI in patients with heart attack results in suboptimal blood flow to the heart muscle, resulting in excessive heart damage. We are hopeful that this trial will demonstrate that the MGuard technology improves the success rate of PCI and clinical outcomes in patients with heart attacks."

Mr. Ofir Paz, CEO of InspireMD said "The initiation of this trial is a very important milestone in our continuous effort to supply compelling evidence based information on MGuard to the cardiology community. We are committed to pursue our clinical program and demonstrate MGuard superiority over standard care."

The trial will run in Europe, South America and Israel with principal investigators, Dr. Alexandre Abizaid, Dr. Dariusz Dudek and Prof. Chaim Lotan.

About MGuard(TM) Coronary

MGuard(TM) presents a novel combination of a coronary stent merged with an embolic protection specifically designed for Acute MI patients. The embolic protection is comprised of an ultra-thin polymer mesh sleeve that wraps the stent. The MGuard(TM) coronary stent provides permanent embolic protection, without affecting deliverability. MGuard(TM) is CE Mark approved. The MGuard(TM) Coronary's innovative concept has enjoyed an enthusiastic welcome from leading interventional cardiologists around the world.

About InspireMD

InspireMD is an innovative medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The company intends to apply its technology to develop products used in interventional cardiology and other vascular procedures. InspireMD's mission is to utilize its proprietary technology to make its products the industry standard for stents and to provide a superior solution to the key clinical issues of current stenting: restenosis, embolic showers, and late thrombosis. In addition to providing embolic protection and minimizing arterial injury, this promising technology can be an effective and uniform drug delivery mechanism with the help of the novel micron-level net for next generation drug eluting stents. InspireMD intends to pursue applications of this technology both for bare metal and drug eluting stents in coronary, carotid and peripheral artery procedures.

Contact details: Jonina Ohayon Marketing Director Tel +972-52-5791120

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Inspired by a cotton candy machine, engineers put a new spin on creating tiny nanofibers
2. Haydon Kerk Motion Solutions Inspires Next Generation of Innovators as Silver Supplier of the FIRST Robotics Competition
3. InspireMD Announces the Enrollment of the 1st Patient in the MGuard(TM) Israeli Registry. InspireMD Will Also Sponsor a Satellite Program Breakfast Meeting at the TCT Conference on September 24th 2009 in the Moscone Exhibition Center in San Francisco
4. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
5. MGuard(TM), InspireMDs Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008
6. Suzanne Somers, Renowned Author, Medical Advocate, and Official Spokesperson for NeoStem, Inc., Inspires the Audience on The Ellen Degeneres Show
7. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
8. $1.6 Million Agreement to Accelerate Fragile X Research, Inspire Hope
10. GeneLink Announces HelixLife Private Label Distribution Agreement
11. SCARGUARD LABS, LLC Announces Key Consumption Results Fastest Growing Brand and Second in Total Rankings
Post Your Comments:
(Date:11/24/2015)... 24, 2015 Cepheid (NASDAQ: CPHD ) ... the following conference, and invited investors to participate via ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ...      Tuesday, December 1, 2015 at 11.00 a.m. Eastern ... New York, NY      Tuesday, December 1, ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... But unless it is bound to proteins, copper is also toxic to cells. ... at Worcester Polytechnic Institute (WPI) will conduct a systematic study of copper in ...
(Date:11/24/2015)... 2015  Clintrax Global, Inc., a worldwide provider of clinical research ... announced that the company has set a new quarterly earnings record ... quarter growth posted for Q3 of 2014 to Q3 of 2015. ... Mexico , with the establishment of an Asia-Pacific ... United Kingdom and Mexico ...
(Date:11/24/2015)... , ... November 24, 2015 , ... The Academy of ... Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person ... few years. Many AMA members have embraced this type of racing and several new ...
Breaking Biology Technology:
(Date:10/27/2015)... -- Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ... that they can be quantitatively analyzed with SMI,s analysis ... , October 28-29, 2015. SMI,s Automated Semantic Gaze ... tracking videos created with SMI,s Eye Tracking Glasses ...
(Date:10/26/2015)...  Delta ID Inc., a company focused on bringing ... devices, announced its ActiveIRIS® technology powers the iris recognition ... by NTT DOCOMO, INC in Japan ... to include iris recognition technology, after a very successful ... May 2015, world,s first smartphone to have this capability. ...
(Date:10/22/2015)... SYNA ), a leading developer of human interface solutions, today reported ... --> --> Net revenue for ... comparable quarter last year to $470.0 million. Net income for the ... diluted share. --> --> ... 39 percent over the prior year period to $56.9 million, or ...
Breaking Biology News(10 mins):